To investigate the role of mTOR inhibition in alleviating clinical symptoms of ME/CFS, we initiated an observational trial with low-dose, once weekly (6 mg/wk) Rapamycin (sirolimus), an mTOR inhibitor, in ME/CFS subjects. Here, MTOR is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.